Search

Your search keyword '"De Socio, G. V."' showing total 114 results

Search Constraints

Start Over You searched for: Author "De Socio, G. V." Remove constraint Author: "De Socio, G. V."
114 results on '"De Socio, G. V."'

Search Results

1. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?

3. Weight Gain: A Possible Side Effect of All Antiretrovirals

4. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

7. Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria

8. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia A Randomized Clinical Trial

9. Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study

10. Delivery in Asymptomatic Italian Woman with SARS-CoV-2 Infection

12. Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort

13. Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible from the STOPSHIV Project Cohort

15. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

16. Predictors of severe weight gain in patients treated with Dolutegravir

18. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

19. Dolutegravir safety in a real-life setting: results from the SCOLTA cohort

21. Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study

22. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)

23. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

26. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)

29. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance

30. Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project

31. Weight gain: A possible side effect of all antiretrovirals

32. Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?

33. Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: The HIVand Hypertension Study

35. Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study

36. Effectiveness of first-generation HCV protease inhibitors: Does HIV coinfection still play a role?

37. IS THERE A RELATION BETWEEN MYALGIA AND CENTRAL NERVOUS SYSTEM SYMPTOMS IN PATIENTS RECEIVING RALTEGRAVIR? RESULTS FROM THE SCOLTA PROJECT

38. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals

39. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance

40. NRTI-sparing regimen in clinical practice: the SCOLTA cohort

41. Muscle symptoms and creatinine phosphokinase elevations in patients receveiving raltegravir in clinical practice: results from a multi center study

43. Decreasing cardiovascular risk in HIV infection between 2005 and 2011

44. Risultati preliminari sulla sicurezza di atazanavir/ritonavir (ATZ/RTV) nella terapia antiretrovirale di una coorte di pazienti HIV-1 positivi arruolati nel progetto Scolta

46. Tossicità in HAART contenente Lopinavir/r: Risultati di uno studio di coorte (Progetto Scolta)

47. The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients

48. The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: Results from a prospective study

49. Low frequency of skin reactions in a cohort of patients on raltegravir

50. Waist circumference and body mass index in HIV infection

Catalog

Books, media, physical & digital resources